What is it?
Identity and source
1Ethyl apovincaminate is another name for vinpocetine. FDA describes synthetic production from plant-derived precursors; vinpocetine itself is not a natural constituent of periwinkle or other plants.
The early memory signal was narrow
5A 1985 crossover study enrolled 12 healthy women. Following two days of three-times-daily dosing, one memory-scanning measure improved in the highest-dose condition. Choice reaction time, flicker-fusion testing and subjective ratings did not improve. This brief result does not establish a practical long-term regimen.
Older dementia studies answer a different question
3Cochrane included three older trials with 583 people with dementia. Some measures favored vinpocetine, but diagnostic criteria, reporting limitations and few longer observations left the evidence inconclusive. These patient results cannot establish healthy-user benefit.
A later pilot found no cognitive benefit
6In 2021, eight healthy adults received placebo and single oral doses of 10, 20 and 60 mg in a randomized crossover study. No significant cognitive benefit or appreciable side effects were reported. A separate eight-person epilepsy cohort also showed no cognitive benefit. The small samples cannot settle efficacy or uncommon harm.
Names, aliases and forms
Mechanisms of action
Proposed vascular and cellular actions
7The oral monograph describes effects on ion channels, cell signalling and cerebral circulation. These mechanisms alone do not demonstrate better memory.
Potential effects and evidence map
Human findings are limited and mixed: a small early experiment found a task-specific memory signal, while a later randomized pilot found no significant cognitive benefit. Older dementia trials provide a different population and remain inconclusive. Reliable everyday cognitive enhancement in healthy adults has not been established.
A small early study reported an isolated memory-task signal; a later pilot found no cognitive benefit. Everyday memory improvement remains uncertain.
The later healthy-volunteer pilot did not show significant cognitive improvement across its test battery.
The early experiment found no significant change in alertness-related testing or subjective drug-effect ratings.
Vascular and cellular hypotheses have not established long-term brain-health outcomes in healthy users.
Typical dosages and timing
The Polish Cavinton label divides this daily amount into three doses after meals. This is medicine-label context; a nootropic dose for healthy self-use is unestablished.
Timing & effect horizon
The oral monograph reports a plasma peak at about one hour and a human The time for blood levels to fall by half during the final elimination phase.Source of 4.83 ± 1.29 hours. The featured half-life is rounded. These plasma measurements do not establish cognitive onset or duration.
Safety, side effects and risk profile
FDA advises against use during pregnancy or when pregnancy is possible because of potential fetal harm.
The oral leaflet lists uncommon blood-pressure changes, usually decreases, and ECG/rhythm abnormalities whose causal link is uncertain.
Headache, dizziness and weakness are labelled uncommon and may also reflect the underlying illness.
Small and short healthy-volunteer studies cannot establish safety during repeated long-term self-use.
The monograph calls for caution with anticoagulants, antiarrhythmics and centrally acting medicines; alpha-methyldopa can have greater blood-pressure effects.
Uncommon reports include blood-pressure reductions, sleep disturbance, nausea, heartburn, skin allergy and liver-enzyme elevations. ECG/rhythm reports have uncertain causality. Rare reports include leukopenia (a low white blood-cell count) and abdominal pain. These patient-label reports do not establish the incidence of harm in healthy users.
Interactions and cautions
The monograph notes occasional enhanced blood-pressure lowering with alpha-methyldopa and cautions about anticoagulants, antiarrhythmics and centrally acting medicines. It recommends ECG monitoring for prolonged QT or concurrent QT-prolonging medicines.
QT is an electrical timing interval measured on an ECG, a recording of electrical activity in the heart. A prolonged interval can disturb heart rhythm.
Legal and regulatory status
As of 13 October 2026, FDA describes its 2016 conclusions on dietary-ingredient eligibility and exclusion after prior drug investigation as tentative. Retail availability is not FDA approval; this U.S. position is not a worldwide ban.
Checked 13 October 2026: Gedeon Richter lists Cavinton 5 mg tablets as prescription-only in Poland. That product-specific status does not establish import eligibility or supplement status elsewhere in the EU or internationally.
How it compares
A botanical extract name does not establish a vinpocetine amount. For like-for-like comparison, use the explicitly declared compound strength.
For illustration, 50 tablets labelled 5 mg each contain 250 mg in total. That arithmetic compares packages; it is not a dosing schedule. A bulk powder price per gram answers a different question from price per finished tablet.
Practical buying and quality notes
- Compare ingredient-specific milligrams, route and pack count. Combination formulas need a separate amount for each ingredient. Some catalog titles mix tablet and ampoule options; their form labels and normalized prices need correction. Confirm the selected variant before interpreting a price, and keep injectable products separate from oral comparisons.
FAQ
Is a higher dose more effective?
6That has not been established. The later pilot found no cognitive benefit across its single-dose conditions, and its small size cannot justify dose escalation or routine self-use.
How long should a vinpocetine cycle last?
6No cycle length has been validated for healthy users. The short healthy-volunteer pilot cannot establish a sustained-benefit schedule or the safety of repeated long-term use.
References
- U.S. Food and Drug Administration. Vinpocetine in Dietary Supplements.
- PubChem Compound Summary for Vinpocetine. National Center for Biotechnology Information.
- Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews. 2003.
- Catlin N, Waidyanatha S, Mylchreest E, Miller-Pinsler L, Cunny H. Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit. Birth Defects Research. 2018.
- Subhan Z, Hindmarch I. Psychopharmacological effects of vinpocetine in normal healthy volunteers. European Journal of Clinical Pharmacology. 1985;28:567-571.
- Meador KJ, Leeman-Markowski B, Medina AE, et al. Vinpocetine, cognition, and epilepsy. Epilepsy & Behavior. 2021;119:107988.
- Polish medicinal-product register. Cavinton 5 mg tablets: Summary of Product Characteristics, sections 4.2-4.8 and 5.2.
- Gedeon Richter. Cavinton 5 mg tablets: Polish patient information leaflet. May 2021.
- Gedeon Richter Poland. Cavinton: product information.
- National Heart, Lung, and Blood Institute. Long QT Syndrome.